Telix and United Imaging Announce Strategic Theranostics Collaboration
Globe Newswire (Tue, 2-Jun 7:00 AM ET)
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Globe Newswire (Mon, 1-Jun 5:00 PM ET)
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
Globe Newswire (Wed, 27-May 7:00 AM ET)
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Globe Newswire (Mon, 18-May 5:00 PM ET)
Globe Newswire (Fri, 15-May 6:30 AM ET)
Globe Newswire (Thu, 14-May 7:30 AM ET)
New Publication Demonstrates TLX250-Px (Zircaix) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Globe Newswire (Mon, 4-May 5:00 PM ET)
TLX101-Px (Pixlumi) MAA Accepted in Europe
Globe Newswire (Thu, 30-Apr 5:43 PM ET)
Globe Newswire (Wed, 29-Apr 5:00 PM ET)
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next-Generation Portfolio Approach
Globe Newswire (Mon, 27-Apr 7:27 PM ET)
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Telix Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol TLX.
As of June 9, 2026, TLX stock price climbed to $9.37 with 51,048 million shares trading.
TLX has a beta of 0.92, meaning it tends to be less sensitive to market movements. TLX has a correlation of 0.04 to the broad based SPY ETF.
TLX has a market cap of $3.14 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that TLX belongs to (by Net Assets): APIE.
TLX has underperformed the market in the last year with a return of -44.1%, while SPY returned +23.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TLX shares. However, TLX has outperformed the market in the last 3 month and 2 week periods, returning +24.6% and -1.1%, while SPY returned +8.8% and -2.2%, respectively. This indicates TLX has been having a stronger performance recently.
TLX support price is $8.93 and resistance is $9.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLX shares will trade within this expected range on the day.